EFFECT OF DANAZOL IN TREATMENT OF CHRONIC CYSTIC MASTITIS

Abstract

Danazol in a dose of 400 mg daily was administered to 40 patients with chronic cystic mastitis and resulted in a marked improvement in both objective and subjective symptoms in 87.5% of the patients studied. Three patients showed partial relief of symptoms and 1 patient showed no improvement after 1 mo. of treatment at which time she withdrew from the study. One patient had a worsening of her condition and was withdrawn from the study after 3.5 mo. of therapy. Nineteen of the 40 patients in the study had a secondary diagnosis of pelvic endometriosis confirmed histologically, and all these patients showed a marked improvement of symptoms during the Danazol treatment. Patients developed amenorrhea after 3-4 mo. of Danazol therapy, and symptoms such as dysmenorrhea, premenstrual pelvic pain and tension abated at the same time. A mild, but well-tolerated weight gain was the major side effect of Danazol administration. No significant changes in the levels of plasma E1[estrone], E2[estradiol],FSH [follicle stimulating hormone], LH [luteinizing hormone] or progesterone could be demonstrated in specimens drawn from 11 patients before and during the course of Danazol administration.